AAAAAA

   
Results: 1-13 |
Results: 13
Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome
Authors: Seipelt, G Bohme, A Koschmieder, S Hoelzer, D
Citation: G. Seipelt et al., Effective treatment with rituximab in a patient with refractory prolymphocytoid transformed B-chronic lymphocytic leukemia and Evans syndrome, ANN HEMATOL, 80(3), 2001, pp. 170-173
TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34(+) cells from healthy donors, but not from patients with AML after MDS
Authors: Koschmieder, S Hofmann, WK Kunert, J Wagner, S Ballas, K Seipelt, G Hoelzer, D Ottmann, OG Kalina, U
Citation: S. Koschmieder et al., TGF beta-induced SMAD2 phosphorylation predicts inhibition of thymidine incorporation in CD34(+) cells from healthy donors, but not from patients with AML after MDS, LEUKEMIA, 15(6), 2001, pp. 942-949
Black tea delays recovery from iron-deficiency anemia
Authors: Mahlknecht, U Weidmann, E Seipelt, G
Citation: U. Mahlknecht et al., Black tea delays recovery from iron-deficiency anemia, HAEMATOLOG, 86(5), 2001, pp. 559-559
Cytokine therapy for myelodysplastic syndrome
Authors: Seipelt, G Ottmann, OG Hoelzer, D
Citation: G. Seipelt et al., Cytokine therapy for myelodysplastic syndrome, CURR OPIN H, 7(3), 2000, pp. 156-160
Defective megakaryocytic development in myelodysplastic syndromes
Authors: Hofmann, WK Kalina, U Koschmieder, S Seipelt, G Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Defective megakaryocytic development in myelodysplastic syndromes, LEUK LYMPH, 38(1-2), 2000, pp. 13-19
Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels
Authors: Hofmann, WK Seipelt, G Ottmann, OG Kalina, U Koschmieder, S Brucher, J Frickhofen, N Klausmann, M Mitrou, PS Hoelzer, D
Citation: Wk. Hofmann et al., Effect of treatment with amifostine used as a single agent in patients with refractory anemia on clinical outcome and serum tumor necrosis factor alpha levels, ANN HEMATOL, 79(5), 2000, pp. 255-258
Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML)
Authors: Ganser, A Heil, G Seipelt, G Hofmann, W Fischer, JT Langer, W Brockhaus, W Kolbe, K Ittel, H Brack, N Fuhr, HG Knuth, P Hoffken, K Bergmann, L Hoelzer, D
Citation: A. Ganser et al., Intensive chemotherapy with idarubicin, ara-C, etoposide, and m-AMSA followed by immunotherapy with interleukin-2 for myelodysplastic syndromes and high-risk Acute Myeloid Leukemia (AML), ANN HEMATOL, 79(1), 2000, pp. 30-35
New aspects of the treatment of patients with low-risk myelodysplastic syndromes
Authors: Hofmann, WK Seipelt, G Kalina, U Hoelzer, D
Citation: Wk. Hofmann et al., New aspects of the treatment of patients with low-risk myelodysplastic syndromes, ONKOLOGIE, 23(1), 2000, pp. 12-16
Clinical use of hematopoietic growth factors
Authors: Seipelt, G
Citation: G. Seipelt, Clinical use of hematopoietic growth factors, ANTIB CHEMY, 50, 2000, pp. 94-105
Reactive hemophagocytic syndrome with involvement of the spleen, splenic-hilum lymph nodes, bone marrow and the liver
Authors: Wassmann, B Seipelt, G Langer, F Rummel, M Bohme, A Hansmann, ML Hoelzer, D
Citation: B. Wassmann et al., Reactive hemophagocytic syndrome with involvement of the spleen, splenic-hilum lymph nodes, bone marrow and the liver, INTERNIST, 41(3), 2000, pp. 304
Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor
Authors: Hofmann, WK Ganser, A Seipelt, G Ottmann, OG Zander, C Geissler, G Hoffmann, K Hoffken, K Fischer, JT Isele, G Hoelzer, D
Citation: Wk. Hofmann et al., Treatment of patients with low-risk myelodysplastic syndromes using a combination of all-trans retinoic acid, interferon alpha, and granulocyte colony-stimulating factor, ANN HEMATOL, 78(3), 1999, pp. 125-130
Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha
Authors: Hofmann, WK Kalina, U Seipelt, G Hoffmann, K Wagner, S Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Megakaryocytic growth in patients with refractory anemia is suppressed by treatment with interferon alpha, EUR J HAEMA, 62(5), 1999, pp. 336-340
Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes
Authors: Hofmann, WK Kalina, U Wagner, S Seipelt, G Ries, C Hoelzer, D Ottmann, OG
Citation: Wk. Hofmann et al., Characterization of defective megakaryocytic development in patients with myelodysplastic syndromes, EXP HEMATOL, 27(3), 1999, pp. 395-400
Risultati: 1-13 |